Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

458
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
458
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

183
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
183
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

278
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
278
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

215
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
215
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

180
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
180

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Application of integrated whole-course clinical learning combined with case-based learning in undergraduate otolaryngology clerkships.

BMC medical education·2026
Same author

Precision prebiotics: Engineering food-derived polysaccharides to target specific SCFA-producing taxa for neuroprotection via the microbiota-gut-brain axis.

Current research in food science·2026
Same author

A Multi-Task Segmentation and Classification Network Based on Ultrasound Images for Predicting the Grading of Ascites in the Abdominal Cavity.

Ultrasonic imaging·2026
Same author

Targeting the Myocardial Microenvironment: Novel Antiviral Strategies and Therapeutic Perspectives for Coxsackievirus B-Induced Myocarditis.

Journal of the American Heart Association·2026
Same author

Developing High Performance N-Oxygenase for Azomycin Synthesis through Ancestral Sequence Reconstruction.

ACS synthetic biology·2026
Same author

Application of single-cell transcriptomic technology in cell fate determination of embryonic liver.

Histology and histopathology·2026

Video Experimental Relacionado

Updated: Jul 10, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.3K

Ubrogepant para el tratamiento de los ataques de migraña durante el prodromo: un ensayo cruzado de fase 3,

David W Dodick1, Peter J Goadsby2, Todd J Schwedt3

  • 1Department of Neurology, Mayo Clinic, Phoenix, AZ, USA; Atria Academy of Science and Medicine, New York, NY, USA.

Lancet (London, England)
|November 18, 2023
PubMed
Resumen
Este resumen es generado por máquina.

Ubrogepant trató eficazmente los ataques de migraña cuando se administró durante la fase de prodromo, reduciendo significativamente la gravedad del dolor de cabeza en comparación con el placebo. Este antagonista del receptor del péptido relacionado con el gen de la calcitonina (CGRP, por sus siglas en inglés) demostró una buena tolerabilidad en el ensayo PRODROME.

Más Videos Relacionados

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

820
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

3.8K

Videos de Experimentos Relacionados

Last Updated: Jul 10, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.3K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

820
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

3.8K

Área de la Ciencia:

  • Neurología
  • Farmacología

Sus antecedentes:

  • La migraña es un trastorno neurológico debilitante.
  • La fase de prodromo precede al inicio del dolor de cabeza de la migraña.
  • Ubrogepant es un antagonista de los receptores CGRP para el tratamiento de la migraña aguda.

Objetivo del estudio:

  • Evaluar la eficacia y seguridad de ubrogepant 100 mg para el tratamiento de la migraña durante el prodromo.
  • Para comparar el ubrogepant con el placebo en la fase más temprana de un ataque de migraña.

Principales métodos:

  • Estudio cruzado de fase 3, aleatorizado, doble ciego, controlado con placebo (PRODROME).
  • Los adultos con migraña episódica recibieron ubrogepant 100 mg o placebo durante el prodromo.
  • Objetivo primario: ausencia de dolor de cabeza moderado/severo en las 24 horas.

Principales resultados:

  • Ubrogepant redujo significativamente el dolor de cabeza moderado/ severo (46% frente al 29% para el placebo, OR 2,09, p< 0,0001).
  • Las reacciones adversas fueron ligeramente mayores con ubrogepant (17% frente al 12% para placebo).

Conclusiones:

  • Ubrogepant 100 mg es eficaz y bien tolerado para el tratamiento de la migraña iniciada durante el prodromo.
  • La intervención temprana con ubrogepant durante el prodromo ofrece una estrategia de tratamiento viable.